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Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disorder, 
characterized by a diverse etiopathology. While ALS is predominantly sporadic, 
mutations in one or more of a dozen risk factors have been linked to approximately 
10% of familial ALS patients. The multifunctional RNA/DNA-binding protein 
fused in sarcoma (FUS) is one such protein whose autosomal dominant missense 
mutations were identified in a subset of familial and sporadic ALS patients. Initial 
studies linked FUS with both RNA-related and genome maintenance functions, 
yet the mechanisms and potential implications to neurodegeneration were not 
completely understood. We recently identified a novel function of FUS in repair-
ing single-strand break (SSB) in the genome. FUS directly interacts and recruits 
XRCC1/DNA Ligase IIIα (LigIII) to DNA oxidative damage sites in a PARP1 activity-
dependent manner, which facilitates optimal oxidative genome damage repair. 
Besides, FUS regulates DNA strand break sealing by enhancing ligation activity of 
LigIII. The mutation of FUS induces accumulation of oxidative DNA damage as well 
as DNA repair deficiency in ALS patients. The novel findings provide insights into a 
previously undescribed mechanism of DNA repair defect in FUS-associated neuro-
degeneration, and raise the pentientials of developing neuroprotective therapies by 
targeting DNA break ligating defects.
Keywords: FUS, neurodegeneration, DNA repair, oxidative genome damage,  
XRCC1-DNA ligase III
1.  Fused in sarcoma (FUS): pathophysiology and links to familial 
and sporadic ALS
1.1 FUS and its physiological functions
The FUS/TLS (Fused in sarcoma Protein/Translocated in liposarcoma) gene 
encodes a 526-amino acid protein that belongs to the TET (TAF15, EWS, and TLS) 
family, which is implicated in multiple aspects of RNA metabolism. The FUS gene 
was initially identified as an oncogene in multiple cancers. FUS fuses with the 
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transcription repressor C/EBP homologous protein 10 (CHOP) in myxoid liposar-
comas. It was identified for its role as an activator of ETS-related gene (ERG) in 
acute myeloid leukemia [1, 2] and in Ewing’s sarcoma tumors [3]. Subsequently, 
mutations in FUS were linked to motor neuron diseases, amyotrophic lateral sclero-
sis (ALS), and frontotemporal dementia (FTD) [4, 5].
FUS protein is ubiquitously expressed in both the nucleus and cytoplasm of 
many cell types; however, it is predominantly found in the nucleus of glial cells and 
neurons in the central nervous system. A small fraction of FUS shuttles between 
the nucleus and cytoplasm under various stimuli, for example, sodium arsenite-
induced oxidative stress [6, 7]. A previous study revealed that FUS binds RNA in 
vivo to engage in nucleo-cytoplasmic shuttling [8]. Another study showed that 
FUS is localized to dendritic spines as an RNA-protein complex and associates with 
mRNA encoding an actin-stabilizer protein, which indicates a regulatory role of 
FUS in actin/cytoskeleton processes in dendrites [9]. Interestingly, in response 
to stress-induced by sorbitol, FUS redistributes to the cytoplasm and localizes 
to cytoplasmic stress granules [10], a complex comprised of mRNA, ribosomes, 
RNA-binding proteins, transcription factors and nucleases that form in response 
to induced stress, such as oxidative stress and heat shock to maintain the stabil-
ity of selected mRNAs and protein activities [11, 12]. The redistribution of FUS 
on stress granules is regulated by posttranslational modification, methylation, 
and highly related with cell survival from the stress [10]. FUS protein contains 
an SYGQ-rich region at its N terminal, followed by a RGG box (RGG1), an RRM 
motif, a second RGG box (RGG2), a zinc finger (ZnF) motif, and a third RGG box 
(RGG3). The C-terminus contains a nonclassical nuclear localization signal (NLS) 
with conserved proline and tyrosine residues (PY-NLS). The 13 terminal amino 
acids (514–526) containing the NLS sequence were shown to be necessary, but not 
sufficient, for nuclear import of FUS [13]. FUS can bind with RNA and both single-
stranded (ss) as well as double-stranded (ds) DNA [14]. FUS is associated with 
multiple roles in RNA processing, including splicing, transcription, and transport. 
Studies have highlighted that FUS has a transcriptional regulatory role in global or 
specialized components of transcriptional machinery [15]. A Clip-seq based study 
revealed that FUS regulates alternative splicing of pre-mRNAs and processing of 
long-intron containing transcripts, and the RNAs targeted by FUS are associated 
with neurogenesis and gene expression regulation; interestingly, some of FUS’ 
mRNA targets are involved in DNA damage response and repair pathways [16].
1.2 FUS is mutated in both familial and sporadic ALS
The prevalence of ALS has been observed to be non-uniform geographically 
but ranges between 0.6 and 3.8 per 100,000 population worldwide. The rate of 
ALS incidence appears to be rising according to the recent epidemiological studies, 
despite the geographical differences [17]. Notably, the incidence and prevalence 
of ALS are greater in men than in women [18]. It has been reported that the male: 
female ratio is between 1 and 3 and changes in an age-dependent manner [19]. 
In approximately 90% of ALS cases the cause is unknown, and, as such, they 
are considered sporadic (SALS); while, around 10% of ALS patients have a clear 
family history (FALS). In 2009, two independent studies identified that FUS R521 
is mutated in FALS cases and that mutation is characterized pathologically with 
enhanced cytoplasmic inclusions of FUS and motor neuron degeneration [4, 5]. 
FUS mutations have also been linked to cases of SALS [20–22]. The FUS gene is 
composed of 15 exons and most mutations are clustered in exon15. Exon15 encodes 
the NLS domain, implying a possible involvement of its nuclear import defects. 
These mutations/truncations include 495X, R521C/G/H/L/S, R522G, P525L, and so 
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on. R521 is the most commonly mutated site in ALS, whereas P525 mutations are 
highly related with early onset and severe progress of ALS [23–25]. Mutations also 
occur in domains other than NLS. For example, G187S within Gly-rich domain, 
G399V in RGG domain, and P431L in ZnF domain [26], which is believed to induce 
functional defects of FUS. Autosomal dominant mutations in the gene encoding the 
FUS protein have been detected in approximately 5% of FALS patients and a small 
subset (~1%) of SALS cases.
1.3 FUS pathology in FTD
It is important to note that many ALS patients (36–51%) also exhibit cognitive 
impairment, with about 20% developing FTD, also called frontotemporal lobar 
degeneration (FTLD) [27], a disorder characterized by cognitive, behavioral, and 
linguistic dysfunction. The reverse is also seen, wherein patients with FTD can 
develop ALS [28]. FTD accounts for 10–15% of dementias, making it the second 
most common type of dementia for people under the age of 65, after Alzheimer’s 
disease. The overlap between ALS and FTD indicates a likely common molecular 
basis between FUS and cognitive deficits. After the discovery of FUS mutation 
in ALS, a novel subtype of FTD with FUS pathology was identified, although no 
FUS mutation was seen [29]. In 2010, Oriane Broustal et al. identified three exonic 
FUS variants, c. 1562G > A (p.Arg521His), c. 1566G > A (p.Arg522Arg), and 
c.188A > G (pAsn63Ser) from 317 patients including 144 patients with familial 
FTD and 173 patients with FTD-ALS. Interestingly, the three variants were found 
only in patients with both FTD and ALS [27].
2. Multifaceted role of FUS in RNA and DNA transactions
The molecular mechanisms of FUS-ALS are complex and ambiguous, typi-
cally described by both loss of function and gain of toxicity hypotheses. Although 
controversial, loss of function is not entirely supported by animal models: FUS 
knockout mice and zebrafish do not develop ALS-like phenotypes [30–32]. As 
mentioned in the previous section, FUS plays multiple roles in RNA metabolism. In 
fact, thousands of RNA targets have been identified that bind to FUS in various cell 
lines and brain tissue from both patients and animal models [33]. The dysregula-
tion and disturbance of RNA processing are considered to be one mechanism that 
leads to neurodegeneration. Depletion of FUS in mouse nervous system has been 
shown to alter the levels of splicing of over 950 mRNAs [34]; FUS knockout in 
neuroblastoma cells disturbs the splicing of more than 400 introns [35]. Expression 
of FUS P525L mutant was shown to inhibit splicing of minor introns by trapping 
U11 and U12 small nuclear RNAs (snRNAs) in these aggregates [35], and expression 
of R521G and R522G mutations influence RNA transcription and splicing but in a 
different way [36]. Besides, mRNA transport and stabilization are also affected by 
ALS-linked FUS mutations [37, 38].
The majority of the mutations occur in the NLS region of FUS, which induces its 
cytoplasmic accumulation. The widespread FUS mislocalization has been consid-
ered a hallmark of ALS [39]. Mutant, but not the wild-type FUS was shown to be 
assembled into stress granules in cytoplasm in response to oxidative stress or heat 
shock [7, 40], which potentially contributes to neurotoxicity by impairing mRNA 
translation [41, 42]. In fact, mutations in RNA-binding proteins (RBPs) are highly 
related to ALS. The interaction between mistranslocated FUS and other RBPs was 
recently investigated. These studies show that the cytoplasmic mislocalization 
caused by FUS P525L mutation impairs its interaction with other ALS-associated 
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RBPs including shnRNPA1, hnRNPA2B1, EWSR1, and TAF15, which facilitates the 
nucleation of toxic cytoplasmic FUS aggregates. In addition, high cytoplasmic FUS 
levels exhibit defects in protein degradation and reduced protein levels of RBPs, 
shedding lights on the FUS-ALS pathology linked to the homeostasis of multiple 
ALS-associated RBPs [43].
2.1 FUS toxicity and impaired DNA damage response (DDR) signaling
In addition to RNA dysregulation, there has been a lot of focus on the genome 
instability caused by FUS mutation in ALS patients since FUS was first linked 
to DNA damage repair by multiple studies. In human cells, one major source 
of genome damage is the reactive oxygen species (ROS) accumulation-induced 
oxidative stress. ROS that defined as a group of reactive molecules derived from 
oxygen including but not limited to free radicals (superoxide, O2
−), hydroxyl 
radical (·OH), or non-radicals (hydrogen peroxide) can be balanced by various 
antioxidant systems, while the imbalance between ROS production and antioxidant 
defenses causes oxidative stress, leading to oxidation of lipid, protein, and DNA 
in cells [44]. Accumulation of oxidative DNA damge has been linked to multiple 
neurodegenerative diseases like Parkinson’s disease (PD) and Huntington’s disease 
(HD) [45, 46]. In addition to DNA damage, mutation in the genes of specific DNA 
repair pathways that lead to DNA damage repair (DDR) is another challenge for 
the central nervous system [47]. For example, nucleotide excision repair (NER) 
is defective in xeroderma pigmentosum (XP) and Cockayne syndrome (CS), base 
excision/single-strand break repair (BER/SSBR) defects in ataxia with oculomo-
tor apraxia type 1 (AOA1) [48], spinocerebellar ataxia with axonal neuropathy 
(SCAN1) [49] and ALS [50], and defective DDR signaling and DNA double-strand 
break repair (DSBR) in ataxia telangiectasia (A-T) and Nijmegen break-age syn-
drome. FUS is found to be phosphorylated by DDR proteins ataxia-telangiectasia 
mutated (ATM) and DNA-dependent protein kinase (DNA-PK) in response to 
DSB-inducing agents. FUS was identified to interact with histone deacetylase 1 
(HDAC1) in primary mouse cortical neurons, and the interaction is believed to 
modulate the homologous recombination (HR) and non-homologous end join-
ing (NHEJ), two major pathways for DSB repair. Besides, FUS was shown to be 
recruited at DNA damage tracks induced by microirradiation (MIR) at wavelengths 
of 405 or 351 nm, in a PARP1-depedent manner and accompanied with PARylation 
by PARP1 [51–53]. Notably, MIR causes clusters of different types of DNA damage 
including oxidized base lesions, single-strand breaks (SSBs), and DSBs. It is gener-
ally believed that UVA (wavelength between 320 and 400 nm) predominantly 
induces SSBs via elevated ROS, while UVA may also induce secondary DSBs due to 
clustered SSBs [54]. Thus, recruitment of FUS at MIR with wavelength of 351 nm 
suggests its potential role in the repair of SSBs.
2.2 FUS and repair of oxidative genome damage: mechanistic insights
A comprehensive investigation by our group described the mechanistic role of 
FUS in BER/SSBR, a major pathway to repair oxidative DNA damage. Our study 
utilized multiple in vitro and in vivo model systems, including, CRISPR/Cas9-
mediated FUS knockout (KO) human embryonic kidney (HEK)293 cells, FALS 
patient-derived induced pluripotent stem cells (iPSCs) with FUS mutations R521H 
and P525L, motor neurons induced from these iPSC lines, and ALS patients spinal 
cord tissues with FUS pathology. We discovered that the DNA integrity is substan-
tially affected in the spinal cord tissues and the motor neurons derived from ALS 
patients. Both downregulation and pathological mutation of FUS were associated 
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with DNA SSB accumulation and SSBR defects. Finally, we identified that FUS 
directly interacts with PARP1, XRCC1, and LigIII in response to oxidative stress and 
FUS facilitates the recruitment of XRCC1/LigIII to DNA damage sites in a PARP1 
activity-dependent manner. FUS enhances the ligation activity of LigIII, which 
is critical for an optimal SSBR in neurons (Figure 1). The SSBR deficiency due to 
ALS-linked FUS mutations can be rescued by the correction of those mutations via 
Crisper/Cas9 technology [50]. Furthermore, FUS regulates PARP1’s PARylation 
activity in motor neurons and thus could affect neuronal energy metabolism by 
uncoupling NAD+/NADH levels.
2.3 FUS-PARP-1 interactions: a new paradigm with diverse implications
During DDR, PARP1 plays an important role in regulating DNA damage repair. 
In response to DNA damage, PARP1 is self-activated by its auto-PARylation and 
transfers ADP-ribose to create long and branched poly(ADP-ribose) on target 
DNA repair proteins to facilitate their recruitment; for example, PARP1 recruits 
XRCC1 by its PARylation. A study showed that PARP1 likely plays a major role for 
the poly(ADP-ribose) synthesis induced by alkylating agents, since the amount 
of poly(ADP-ribose) can be reduced for around 10 folds (from 60 pmol per mg of 
DNA to 5.85 pmol per mg of DNA) in PARP1 KO cells in the presence of MNNG 
[55], which activates DNA mismatch repair. Consistantly, PARP1 knockout mice are 
Figure 1. 
Model of FUS involving DNA damage response in the nucleus. In response to DNA SSBs, FUS is PARylated and 
recruited to DNA damage sites by PARP1 and the recruitment facilitates the loading of XRCC1 and nuclear 
LigIII (nLigIII) complex, where FUS enhances the ligation activity of LigIII for an optimal SSB ligating. While 
in response to DSB, FUS is associated with HDAC1, which is required for an efficient NHEJ and HR-mediated 
DSB repair. FUS is also phosphorylated by ATM and DNA-PK, although the underlying mechanism is not 
known. Due to its role in the functional activation of LigII, which is involved in MMEJ-mediated DSB repair, 
it is likely that FUS also affects MMEJ, which needs to be investigated.
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highly susceptible to DNA damaging agents and are accumulated with DNA strand 
breaks accompanied with genomic instability in them [56, 57].
In response to DNA damage, FUS is recruited to DNA damage site in a PARP1 
activity-dependent manner [51, 52]. FUS directly binds to PAR synthesized by 
activated PARP1 leading to the formation of damaged DNA-rich compartments 
contributed by its N-terminal low-complexity domain (LCD) and C-terminal RGG 
domains, and the compartments are dissociated by the hydrolysis of PAR by PARG 
[58], which indicates that PAR polymers play an essential role for the recruitment, 
likely through enhancing the FUS droplet formation [59]. While the activation 
of PARP1 can induce shuttling of FUS from nucleus to cytoplasm, which in turn 
enhances FUS aggregate formation and neurodegeneration [58, 60]. Furthermore, 
like FUS, the other two members in TET family, TAF15 and EWSR1 are also 
recruited to MIR-induced DNA damage tracks depending on PARP1 activity [53], 
while the molecular mechanism of the cross-talk between TET family proteins and 
PARP-1 has not been investigated.
3.  Indirect role of FUS in DDR: FUS-directed RNA transactions in DNA 
repair
Although, recent reports from our group and others demonstrate a complex, 
but the direct role of FUS in maintaining genome integrity, whether FUS RNA-
binding activity plays a role in regulating the expression of DDR factors has 
not been investigated. FUS regulates several key steps of RNA metabolism that 
impairs various biological processes. CLIP-seq has been used to identify RNAs 
that FUS targeted in multiple studies [16, 34, 61–65], which reveals an indirect 
role of FUS involving in DDR by regulating RNA transcription. One report 
shows that FUS regulates alternative splicing of pre-mRNAs and processing of 
long-intron containing transcripts in HeLa cells, and FUS binds RNA encoding 
proteins important for DNA damage response and repair pathways. By comparing 
with other CLIP-based assays, a map of FUS RNA targets to DNA DSBR by NHEJ 
and HR is generated in the report and in which, a number of key DDR factors 
such as ATM, 53BP1, MRN11, NBS1 are included [16]. We recently performed 
RT2 PCR arrays for DNA repair and DDR signaling pathways in CRISPR/cas9 
FUS knockout (KO) cells, patient-derived FUS-mutant cells, as well as FUS-ALS 
patient spinal cord autopsy tissue, which revealed significant downregulation of 
DDR factors BRCA1, MSH complex, RAD23B, and DNA ligase 4. Notably, BRCA1 
depletion has been linked to neuronal DNA DSB accumulation and cognitive 
defects in Alzheimer’s disease. The ubiquitin receptor RAD23 functions both in 
nucleotide excision repair and the proteasomal protein clearance pathway and is 
thus linked to amyloid load in neurodegeneration. This study provides evidence 
of FUS pathology-mediated perturbation in the expression of DNA repair and 
DDR signaling factors and thus highlights the intricate connections between FUS, 
genome instability, and neurodegeneration.
4. Conclusions and perspectives
As early as 1982, the defective DNA repair and its possible role in ALS pathology 
was first proposed by Bradley et al. [66], where they hypothesize that abnormal 
DNA in ALS may arise from a deficiency of an isozyme of a DNA repair factor. 
Subsequently, growing evidence suggests that defective DNA repair is a common 
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feature of not only ALS but also several other neurodegenerative diseases, under-
scoring the needs of studying the implications of unrepaired DNA damage in 
neurons affected by neurodegeneration [67], which may lead to novel therapeutic 
strategies.
Our recent studies made a critical breakthrough in this direction by first 
time shedding lights on the molecular insights into the involvement of ALS and 
FTD-associated FUS and other RNA/DNA-binding proteins in specific DNA 
repair failure mechanisms, such as DNA ligation deficiency. While this study 
suggests a potential for DNA ligase complementation strategy, several key 
questions should be addressed to develop DNA repair-based interventions for 
ALS. These are: (1) The role of FUS in mitochondrial genome stability main-
taining. The linkage between FUS and mitochondrial integrity has been estab-
lished by a number of studies. Deng et al. demonstrated interactions between 
FUS and two mitochondrial proteins, mitochondrial chaperonin HSP60 and 
ATP synthase beta subunit ATP5B, in different studies. HSP60 mediates the 
translocation of FUS into mitochondria, and downregulating of HSP60 rescues 
mitochondrial defects and neurodegenerative phenotypes in FUS transgenic 
flies. While interaction between FUS and ATP5B indicates a involvement of FUS 
in the dysregulation of mitochondrial ATP synthesis: expression of wild-type or 
FUS P525L mutant disrupts the formation of the mitochondrial ATP synthase 
supercomplexes and suppresses the activity of ATP synthase, resulting in mito-
chondrial cristae loss followed by mitochondrial fragmentation [68, 69]. Nakaya 
and Maragkakis et al. found that expression of human FUS R495X in mouse 
embryonic stem cell-differentiated neurons disturbs the translation efficiency 
of mitochondria-associated genes and results in significant reduction of mito-
chondrial size [70]. Although ALS-FUS has been linked with the dysfunction of 
mitochondria, the role of FUS in mitochondrial genome integrity has not been 
explored. (2) The role of FUS in microhomology-mediated end joining (MMEJ) 
repair. We have established a relationship between FUS and XRCC1/LigIII, 
which is required for an optimal SSBR. While LigIII, together with XRCC1 and 
PARP1, also participates in the MMEJ-mediated DSB repair pathway, the role 
of which in primary neurons is unknown (Figure 1). We hypothesized that the 
MMEJ contributes DSBR in motor neurons and the loss of FUS may affect MMEJ 
and lead to genomic instability, which we are currently pursuing. (3) The role of 
FUS in maintaining genome integrity in astrocytes. Recent studies have shown 
that expression of ALS-linked mutant FUS and other ALS causative factors in 
astrocytes induces motor neuron death [71–73]. It will, therefore, be critical to 
investigate FUS toxicity-induced ligation activity defects in astrocytes and the 
collateral influence on motor neurons. (4) Whether DNA ligase I (LigI) rescues 
FUS mutant-mediated LigIII defects. Mammalian cells express three DNA 
ligases including ligase IV (LigIV), LigIII, and LigI. LigIV specifically par-
ticipates in NHEJ-mediated DSB repair; LigIII has nuclear and mitochondrial 
isoforms. Both the nuclear and mitochondrial isoforms have ~98% similarity 
and function in BER/single-strand break repair (SSBR); LigI has been shown 
to functionally overlap with LigIII and is believed a back-up of LigIII, however, 
the level of LigI expression in non-cycling, postmitotic cells like neurons is 
negligible due to lack of replication-associated repair. Very likely, the induction 
of LigI into motor neurons with FUS pathology can rescue the LigIII ligation 
activity defects caused by FUS mutation.
Addressing these critical follow-up questions is an unmet need in the FUS-ALS 
field, which will help to develop a mechanism-based DNA-repair-targeted therapy. 
With recent emerging studies, the stage is set for such a paradigm shift.
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